Key result
Discharge SGLT2i in older HFrEF patients linked to ~24% lower 12-month mortality and fewer HF readmissions.
Why the study?
Randomized trials of SGLT2 inhibitors in HFrEF enrolled relatively younger outpatients, leaving their effectiveness in older patients hospitalized for HFrEF in routine US clinical practice not well studied.
Does SGLT2 inhibitor initiation by hospital discharge reduce mortality and readmissions in older patients hospitalized for HFrEF?
Observational (n=8,847)
Yes
Does SGLT2 inhibitor initiation by hospital discharge reduce mortality and readmissions in older patients hospitalized for HFrEF?
Initiation of SGLT2 inhibitors by hospital discharge in older, real-world Medicare patients with HFrEF is associated with significantly reduced 1-year all-cause mortality and readmissions.
Answers are grounded in this paper and cite their sources.
Supports early SGLT2i initiation at discharge in older HFrEF; extends trial data to Medicare patients while leaving causality open.
Background SGLT2 (sodium‐glucose cotransporter‐2) inhibitors (SGLT2i) reduce cardiovascular events in randomized controlled trials of patients with heart failure with reduced ejection fraction (HFrEF), but these trials enrolled outpatient, relatively younger patients (median age 66–67). The effectiveness of SGLT2i in older patients hospitalized for HFrEF in routine US clinical practice is not well studied. Methods This study included Medicare beneficiaries aged ≥65 years hospitalized for HFrEF and eligible for SGLT2i in Get with the Guidelines–Heart Failure between July 1, 2021 and June 30, 2023. Primary outcomes were 30‐day and 1‐year all‐cause mortality, all‐cause readmission, and HF readmission. Association between SGLT2i and outcomes was assessed with Cox regression and overlap weighting using propensity score estimates. Results A total of 8847 patients were eligible for but not prescribed SGLT2i at hospital admission (Median age 77; 40% women; median left ventricular EF 28%); 1464 (16.5%) patients were initiated on SGLT2i by discharge. After overlap weighting, SGLT2i initiation was independently associated with lower all‐cause mortality (adjusted hazard ratio [HR], 0.76 [95% CI, 0.67–0.86]), all‐cause readmission (HR, 0.89 [95% CI, 0.81–0.97]), and HF readmission (HR, 0.84 [95% CI, 0.75–0.95]) over 12‐month follow‐up, compared with those not prescribed SGLT2i. Findings were consistent across subgroups based on age, sex, race, ethnicity, diabetes status, chronic kidney disease status, and left ventricular EF. Conclusions Among older patients hospitalized for HFrEF, SGLT2i initiation by time of discharge was independently associated with reduced all‐cause mortality, all‐cause readmission, and HF readmission. These findings support SGLT2i use to improve postdischarge outcomes among older patients hospitalized for HFrEF in routine US practice.
No takes yet. Share an insight, caveat, or question.
Brownell et al. (2026) conducted an observational in Heart Failure with Reduced Ejection Fraction (HFrEF) (n=8,847). SGLT2 inhibitors vs. Not prescribed SGLT2 inhibitors was evaluated on 30-day and 1-year all-cause mortality, all-cause readmission, and HF readmission (HR 0.76, 95% CI 0.67-0.86). SGLT2i initiation by discharge among older patients hospitalized for HFrEF was associated with lower 12-month all-cause mortality and HF readmission.
Synapse has enriched 10 related papers. Consider them for comparative context: